{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:44:10Z","timestamp":1782395050424,"version":"3.54.5"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848050005"],"award-info":[{"award-number":["848050005"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40259-023-00592-8","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T10:25:19Z","timestamp":1680517519000},"page":"541-550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2303-6199","authenticated-orcid":false,"given":"Jette A.","family":"van Lint","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi T.","family":"Jessurun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander W.","family":"Tas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald E.","family":"Vonkeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn B. A.","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Hoentjen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Nurmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene P.","family":"van Puijenbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J. F.","family":"van den Bemt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"issue":"Suppl 5","key":"592_CR1","doi-asserted-by":"publisher","first-page":"v35","DOI":"10.1093\/rheumatology\/kez413","volume":"58","author":"SM Korte","year":"2019","unstructured":"Korte SM, Straub RH. Fatigue in inflammatory rheumatic disorders: pathophysiological mechanisms. Rheumatology (Oxford). 2019;58(Suppl 5):v35\u201350.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"592_CR2","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1093\/ecco-jcc\/jjz024","volume":"13","author":"C Chavarr\u00eda","year":"2019","unstructured":"Chavarr\u00eda C, Casanova MJ, Chaparro M, et al. Prevalence and factors associated with fatigue in patients with inflammatory bowel disease: a multicentre study. J Crohns Colitis. 2019;13(8):996\u20131002.","journal-title":"J Crohns Colitis"},{"key":"592_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3899\/jrheum.110902","volume":"88","author":"LA Graff","year":"2011","unstructured":"Graff LA, Walker JR, Russell AS, et al. Fatigue and quality of sleep in patients with immune-mediated inflammatory disease. J Rheumatol Suppl. 2011;88:36\u201342.","journal-title":"J Rheumatol Suppl"},{"issue":"Suppl 5","key":"592_CR4","doi-asserted-by":"publisher","first-page":"v29","DOI":"10.1093\/rheumatology\/kez346","volume":"58","author":"KL Druce","year":"2019","unstructured":"Druce KL, Basu N. Predictors of fatigue in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 5):v29\u201334.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"592_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/BOR.0000000000000376","volume":"29","author":"P Katz","year":"2017","unstructured":"Katz P. Causes and consequences of fatigue in rheumatoid arthritis. Curr Opin Rheumatol. 2017;29(3):269\u201376.","journal-title":"Curr Opin Rheumatol"},{"issue":"20","key":"592_CR6","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.4045\/tidsskr.16.0134","volume":"136","author":"T Grimstad","year":"2016","unstructured":"Grimstad T, Norheim KB. Fatigue in inflammatory bowel disease. Tidsskr Nor Laegeforen. 2016;136(20):1721\u20134.","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"1","key":"592_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/cs0990001","volume":"99","author":"MG Swain","year":"2000","unstructured":"Swain MG. Fatigue in chronic disease. Clin Sci (Lond). 2000;99(1):1\u20138.","journal-title":"Clin Sci (Lond)"},{"issue":"4","key":"592_CR8","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40744-020-00247-y","volume":"7","author":"JM Davis 3rd","year":"2020","unstructured":"Davis JM 3rd, Myasoedova E, Gunderson TM, et al. Multimorbidity and fatigue in rheumatoid arthritis: a cross-sectional study of a population-based cohort. Rheumatol Ther. 2020;7(4):979\u201391.","journal-title":"Rheumatol Ther"},{"issue":"11","key":"592_CR9","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s10067-015-3088-6","volume":"34","author":"P Minnock","year":"2015","unstructured":"Minnock P, Veale DJ, Bresnihan B, et al. Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysis. Clin Rheumatol. 2015;34(11):1857\u201365.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"592_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13075-020-02294-w","volume":"22","author":"G Haugeberg","year":"2020","unstructured":"Haugeberg G, Hoff M, Kavanaugh A, et al. Psoriatic arthritis: exploring the occurrence of sleep disturbances, fatigue, and depression and their correlates. Arthritis Res Ther. 2020;22(1):198.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"592_CR11","volume":"2016","author":"C Almeida","year":"2016","unstructured":"Almeida C, Choy EH, Hewlett S, et al. Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst Rev. 2016;2016(6): CD008334.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"592_CR12","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1097\/RHU.0000000000001293","volume":"27","author":"RML Yip","year":"2021","unstructured":"Yip RML, Yim CW. Role of interleukin 6 inhibitors in the management of rheumatoid arthritis. J Clin Rheumatol. 2021;27(8):e516\u201324.","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"592_CR13","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40257-019-00434-w","volume":"20","author":"IM Skoie","year":"2019","unstructured":"Skoie IM, Dalen I, Omdal R. Effect of biological treatment on fatigue in psoriasis: a systematic review and meta-analysis. Am J Clin Dermatol. 2019;20(4):493\u2013502.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"592_CR14","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1093\/rheumatology\/keaa132","volume":"59","author":"J Shim","year":"2020","unstructured":"Shim J, Dean LE, Karabayas M, et al. Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis. Rheumatology (Oxford). 2020;59(11):3408\u201314.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"592_CR15","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/acr.24517","volume":"74","author":"TK Kvien","year":"2022","unstructured":"Kvien TK, Conaghan PG, Gossec L, et al. secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis: long-term results of two phase III randomized controlled trials. Arthritis Care Res (Hoboken). 2022;74(5):759\u201367.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"592_CR16","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1093\/rheumatology\/keaa115","volume":"59","author":"E Reilly","year":"2020","unstructured":"Reilly E, McGrogan A, Sengupta R. Evaluating patient-reported fatigue and serum biomarkers in axial spondyloarthritis. Rheumatology (Oxford). 2020;59(10):3111\u20133.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"592_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2165\/00044011-200929030-00005","volume":"29","author":"B Lagan\u00e0","year":"2009","unstructured":"Lagan\u00e0 B, Vinciguerra M, D\u2019Amelio R. Modulation of T-cell co-stimulation in rheumatoid arthritis: clinical experience with abatacept. Clin Drug Investig. 2009;29(3):185\u2013202.","journal-title":"Clin Drug Investig"},{"issue":"10","key":"592_CR18","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/rheumatology\/kew241","volume":"55","author":"KL Druce","year":"2016","unstructured":"Druce KL, Bhattacharya Y, Jones GT, et al. Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford). 2016;55(10):1786\u201390.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"592_CR19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00228-015-1877-0","volume":"71","author":"F Wang","year":"2015","unstructured":"Wang F, Lin X, Zhao Q, et al. Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel disease: systematic review and duration-response meta-analysis. Eur J Clin Pharmacol. 2015;71(8):911\u20139.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"592_CR20","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/MEG.0b013e32835aba83","volume":"25","author":"L Vogelaar","year":"2013","unstructured":"Vogelaar L, van\u2019t Spijker A, van Tilburg AJ, et al. Determinants of fatigue in Crohn\u2019s disease patients. Eur J Gastroenterol Hepatol. 2013;25(2):246\u201351.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"9","key":"592_CR21","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s40264-020-00946-z","volume":"43","author":"JA van Lint","year":"2020","unstructured":"van Lint JA, Jessurun NT, Hebing RCF, et al. Patient-reported burden of adverse drug reactions attributed to biologics used for immune-mediated inflammatory diseases. Drug Saf. 2020;43(9):917\u201325.","journal-title":"Drug Saf"},{"issue":"6","key":"592_CR22","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/rheumatology\/kez412","volume":"59","author":"LJ Kosse","year":"2020","unstructured":"Kosse LJ, Jessurun N, Hebing RCF, et al. Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system. Rheumatology (Oxford). 2020;59(6):1253\u201361.","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"592_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/annrheumdis-2020-eular.1310","volume":"79","author":"J Van Lint","year":"2020","unstructured":"Van Lint J, Bakker T, Ubbink J, et al. OP0208: patients report fatigue as an adverse drug reaction of biologics. Ann Rheum Dis. 2020;79(Suppl 1):129\u201330.","journal-title":"Ann Rheum Dis"},{"key":"592_CR24","unstructured":"Remicade\u00ae Product Information: European Medicines Agency [updated 12 Nov 2021; cited 21 Apr 2021]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remicade-epar-product-information_en.pdf."},{"key":"592_CR25","unstructured":"Enbrel\u00ae Product Information: European Medicines Agency [updated 25 Mar 2021; cited 21 Apr 2021]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/enbrel-epar-product-information_en.pdf."},{"key":"592_CR26","unstructured":"Humira\u00ae Product Information: European Medicines Agency [updated 29 Jan 2021; cited 21 Apr 2021]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/humira-epar-product-information_en.pdf."},{"key":"592_CR27","unstructured":"Cimzia\u00ae Product Information: European Medicines Agency [updated 7 Apr 2021; cited 21 Apr 2021]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cimzia-epar-product-information_en.pdf."},{"key":"592_CR28","unstructured":"Simponi\u00ae Product Information: European Medicines Agency [updated 11 Nov 2020; cited 21 Apr 2021]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/simponi-epar-product-information_en.pdf."},{"key":"592_CR29","unstructured":"Orencia\u00ae Product Information: European Medicines Agency [updated 6 Oct 2020; cited 21 Apr 2021]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/orencia-epar-product-information_en.pdf."},{"key":"592_CR30","unstructured":"Kyntheum\u00ae Product Information: European Medicines Agency [updated 27 Jul 2020; cited 21 Apr 2021]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kyntheum-epar-product-information_en.pdf."},{"key":"592_CR31","unstructured":"Ilaris\u00ae Product Information: European Medicines Agency [updated 25 Feb 2020; cited 21 Apr 2021]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ilaris-epar-product-information_en.pdf."},{"key":"592_CR32","unstructured":"Mabthera\u00ae Product Information: European Medicines Agency [updated 25 Mar 2021; cited 21 Apr 2021]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mabthera-epar-product-information_en.pdf."},{"key":"592_CR33","unstructured":"Cosentyx\u00ae Product Information: European Medicines Agency [updated 25 Mar 2021; cited 21 Apr 2021]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf."},{"key":"592_CR34","unstructured":"Stelara\u00ae Product Information: European Medicines Agency [updated 12 Mar 2021; cited 21 Apr 2021]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/stelara-epar-product-information_en.pdf."},{"key":"592_CR35","unstructured":"Entyvio\u00ae Product Information: European Medicines Agency [updated 30 Nov 2020; cited 21 Apr 2021]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/entyvio-epar-product-information_en.pdf."},{"key":"592_CR36","unstructured":"Remicade\u00ae Product Label: US FDA [updated 10 May 2021; cited 2023]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103772s5401lbl.pdf."},{"key":"592_CR37","unstructured":"Cimzia\u00ae Product Label: US FDA [updated 22 Dec 2022; cited 2023]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125160s305lbl.pdf."},{"key":"592_CR38","unstructured":"Siliq\u00ae Product Label: US FDA [updated 15 Feb 2017; cited 2023]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761032lbl.pdf."},{"key":"592_CR39","unstructured":"Stelara\u00ae Product Label: US FDA [updated 29 Jul 2022; cited 2023]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761044s010lbl.pdf."},{"key":"592_CR40","unstructured":"Truxima\u00ae Product Label: US FDA [updated 04 Feb 2022; cited 2023]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761088s018lbl.pdf."},{"key":"592_CR41","unstructured":"Entyvio\u00ae Product Label: US FDA [updated 17 Jun 2022; cited 2023]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125476Orig1s046lbl.pdf."},{"key":"592_CR42","unstructured":"MedDRA Maintenance and Support Services Organization. Medical Dictionary for Regulatory Activities: Northrop Grumman Corporation. http:\/\/www.meddra.org\/."},{"issue":"2","key":"592_CR43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"592_CR44","unstructured":"RoActemra\u00ae Product Information: European Medicines Agency [updated 14 Sep 2020; cited 11 May 2021]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/roactemra-epar-product-information_en.pdf."},{"issue":"6","key":"592_CR45","doi-asserted-by":"publisher","first-page":"R217","DOI":"10.1186\/ar4413","volume":"15","author":"MB \u0106alasan","year":"2013","unstructured":"\u0106alasan MB, van den Bosch OF, Creemers MC, et al. Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther. 2013;15(6):R217.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"592_CR46","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/1744666X.2019.1562905","volume":"15","author":"F Paul","year":"2019","unstructured":"Paul F, Cartron G. Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol. 2019;15(4):383\u20139.","journal-title":"Expert Rev Clin Immunol"},{"issue":"9","key":"592_CR47","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/ecco-jcc\/jjv096","volume":"9","author":"L Lichtenstein","year":"2015","unstructured":"Lichtenstein L, Ron Y, Kivity S, et al. Infliximab-related infusion reactions: systematic review. J Crohns Colitis. 2015;9(9):806\u201315.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"592_CR48","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","volume":"6","author":"U Katz","year":"2007","unstructured":"Katz U, Achiron A, Sherer Y, et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007;6(4):257\u20139.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"592_CR49","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4103\/0019-5154.110832","volume":"58","author":"MK Church","year":"2013","unstructured":"Church MK, Church DS. Pharmacology of antihistamines. Indian J Dermatol. 2013;58(3):219\u201324.","journal-title":"Indian J Dermatol"},{"issue":"6","key":"592_CR50","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40259-021-00507-5","volume":"35","author":"SJ Bots","year":"2021","unstructured":"Bots SJ, Parker CE, Brandse JF, et al. Anti-drug antibody formation against biologic agents in inflammatory bowel disease: a systematic review and meta-analysis. BioDrugs. 2021;35(6):715\u201333.","journal-title":"BioDrugs"},{"issue":"4","key":"592_CR51","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31(4):299\u2013316.","journal-title":"BioDrugs"},{"issue":"2","key":"592_CR52","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/bjd.15375","volume":"177","author":"IM Skoie","year":"2017","unstructured":"Skoie IM, Dalen I, Ternowitz T, et al. Fatigue in psoriasis: a controlled study. Br J Dermatol. 2017;177(2):505\u201312.","journal-title":"Br J Dermatol"},{"issue":"7","key":"592_CR53","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1007\/s00296-011-1876-0","volume":"32","author":"Y Ibn Yacoub","year":"2012","unstructured":"Ibn Yacoub Y, Amine B, Laatiris A, et al. Fatigue and severity of rheumatoid arthritis in Moroccan patients. Rheumatol Int. 2012;32(7):1901\u20137.","journal-title":"Rheumatol Int"},{"issue":"5","key":"592_CR54","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/nur.21813","volume":"40","author":"S Conley","year":"2017","unstructured":"Conley S, Proctor DD, Jeon S, et al. Symptom clusters in adults with inflammatory bowel disease. Res Nurs Health. 2017;40(5):424\u201334.","journal-title":"Res Nurs Health"},{"issue":"8","key":"592_CR55","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1176\/ajp.153.8.1050","volume":"153","author":"S Wessely","year":"1996","unstructured":"Wessely S, Chalder T, Hirsch S, et al. Psychological symptoms, somatic symptoms, and psychiatric disorder in chronic fatigue and chronic fatigue syndrome: a prospective study in the primary care setting. Am J Psychiatry. 1996;153(8):1050\u20139.","journal-title":"Am J Psychiatry"},{"key":"592_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2019.05.005","volume":"123","author":"SM McCallum","year":"2019","unstructured":"McCallum SM, Batterham PJ, Calear AL, et al. Associations of fatigue and sleep disturbance with nine common mental disorders. J Psychosom Res. 2019;123: 109727.","journal-title":"J Psychosom Res"},{"issue":"8","key":"592_CR57","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40264-016-0422-0","volume":"39","author":"L Rolfes","year":"2016","unstructured":"Rolfes L, van Hunsel F, Taxis K, et al. The impact of experiencing adverse drug reactions on the patient\u2019s quality of life: a retrospective cross-sectional study in the Netherlands. Drug Saf. 2016;39(8):769\u201376.","journal-title":"Drug Saf"},{"issue":"3","key":"592_CR58","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s40264-019-00890-7","volume":"43","author":"L Rolfes","year":"2020","unstructured":"Rolfes L, Haaksman M, van Hunsel F, et al. Insight into the severity of adverse drug reactions as experienced by patients. Drug Saf. 2020;43(3):291\u20133.","journal-title":"Drug Saf"},{"issue":"1","key":"592_CR59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2165\/00002018-200831010-00003","volume":"31","author":"TB Agbabiaka","year":"2008","unstructured":"Agbabiaka TB, Savovi\u0107 J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 2008;31(1):21\u201337.","journal-title":"Drug Saf"},{"issue":"12","key":"592_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028096","volume":"6","author":"RM Gallagher","year":"2011","unstructured":"Gallagher RM, Kirkham JJ, Mason JR, et al. Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. PLoS\u00a0One. 2011;6(12): e28096.","journal-title":"PLoS\u00a0One"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00592-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-023-00592-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00592-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T12:41:19Z","timestamp":1687437679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-023-00592-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["592"],"URL":"https:\/\/doi.org\/10.1007\/s40259-023-00592-8","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,3]]},"assertion":[{"value":"1 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jette van Lint, Naomi Jessurun, Michael Nurmohamed, Bart van den Bemt and Eugene van Puijenbroek declare no conflicts of interest. Sander Tas reports grants and\/or personal fees from Abbvie, Arthrogen, AstraZeneca, BMS, Celgene, Galapagos, GSK, MSD, Pfizer, Roche, and Sanofi-Genzyme, all outside the submitted work. Frank Hoentjen has served on advisory boards, or as speaker or consultant for Abbvie, Celgene, Janssen-Cilag, MSD, Takeda, Celltrion, Teva, Sandoz, and Dr Falk; and has received unrestricted grants from Dr Falk, Janssen-Cilag, and Abbvie. Martijn van Doorn has received consulting fees or honorarium from Novartis, Abbvie, Pfizer, Leopharma, Sanofi, Lilly, Janssen, Celgene, and BMS; has received a grant and payment for lectures, including service on speakers bureaus, from Novartis, Sanofi, and Janssen, outside the submitted work. Harald Vonkeman reports grants and\/or personal fees from AbbVie, Amgen, AstraZeneca, BMS, Celgene, Celltrion, Galapagos, Gilead, GSK, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi-Genzyme, and UCB, all outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Dutch Biologic Monitor work was supported by the Netherlands Organisation for Health Research and Development (ZonMw) [grant number 848050005]. No funding was received for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JvL, NJ, and BvdB contributed to the conception and design of this study. JvL and NJ contributed to the analysis and interpretation of the data and drafting of the paper. BvdB, ST, MvD, MN, EvP, FH, and HV critically revised the paper for intellectual content. All authors approved the final version and agree to be accountable for all aspects of this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Ethical approval of the Dutch Biologic Monitor was waived for the Dutch Medical Research Involving Human Subjects Act (WMO) by the Medical Research Ethical Committee of Brabant, The Netherlands (NW2016-66).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The datasets generated and\/or analysed during the current study are not publicly available due to privacy but are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"All participants received information about the Dutch Biologic Monitor prior to participation and signed a digital informed consent form.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent to publish"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}